Assenagon Asset Management S.A. Makes New Investment in The Chemours Company $CC

Key Points

• Assenagon Asset Management acquired 484,104 Chemours shares worth approximately $6.6 million, giving it a 0.32% stake. Institutional investors collectively own 76.26% of the company.
• Analysts remain cautious, with a consensus “Hold” rating and a $17.73 price target; several firms recently lowered ratings or targets.
• Chemours’ latest results fell short of expectations, with revenue declining 1.5% year over year and EPS missing estimates. The stock opened at $12.97, while ongoing demand concerns and potential litigation continue to pressure shares.

Assenagon Asset Management S.A. acquired a new position in shares of The Chemours Company (NYSE:CC - Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 484,104 shares of the specialty chemicals company's stock, valued at approximately $6,569,000. Assenagon Asset Management S.A. owned about 0.32% of Chemours at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of CC. BlackRock Inc. acquired a new stake in Chemours during the second quarter worth approximately $477,769,000. Wolf Hill Capital Management LP purchased a new stake in Chemours in the second quarter valued at $59,698,056. Bank of New York Mellon Corp acquired a new position in Chemours in the second quarter valued at $33,353,000. Bank of America Corp DE boosted its stake in Chemours by 79.1% in the first quarter. Bank of America Corp DE now owns 1,317,003 shares of the specialty chemicals company's stock valued at $29,014,000 after acquiring an additional 581,621 shares in the last quarter. Finally, Legal & General Group Plc acquired a new position in Chemours in the second quarter valued at $28,400,000. Institutional investors and hedge funds own 76.26% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have commented on CC. JPMorgan Chase & Co. cut their price target on Chemours from $22.00 to $15.00 and set a "neutral" rating on the stock in a research report on Thursday, August 13th. Barclays began coverage on shares of Chemours in a report on Monday, October 12th. They issued an "equal weight" rating and a $16.00 target price for the company. Royal Bank Of Canada downgraded shares of Chemours from an "outperform" rating to a "sector perform" rating and set a $14.00 target price for the company. in a research note on Tuesday, October 13th. Weiss Ratings downgraded shares of Chemours from a "sell (d)" rating to a "sell (d-)" rating in a research note on Thursday, August 6th. Finally, Morgan Stanley set a $18.00 price objective on Chemours in a research report on Monday, August 10th. Three equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $17.73.

Chemours Price Performance

CC stock opened at $12.97 on Wednesday. The firm has a 50 day moving average of $14.61 and a 200-day moving average of $18.72. The Chemours Company has a 12-month low of $10.44 and a 12-month high of $28.67. The company has a current ratio of 1.66, a quick ratio of 0.88 and a debt-to-equity ratio of 18.98. The company has a market cap of $1.95 billion, a price-to-earnings ratio of -6.79 and a beta of 1.41.

Chemours (NYSE:CC - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The specialty chemicals company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $0.49 by ($0.07). Chemours had a negative net margin of 5.00% and a positive return on equity of 60.64%. The firm had revenue of $1.59 billion during the quarter, compared to analysts' expectations of $1.65 billion. During the same period in the previous year, the business earned ($2.54) earnings per share. The business's revenue for the quarter was down 1.5% on a year-over-year basis. As a group, equities analysts expect that The Chemours Company will post 0.84 EPS for the current fiscal year.

Chemours Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 15th. Investors of record on Friday, August 14th were paid a $0.0875 dividend. This represents a $0.35 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Friday, August 14th. Chemours's dividend payout ratio is presently -18.32%.

Trending Headlines about Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours said it took action at Chillventa 2026 to protect its refrigerant intellectual property, including technology related to its Opteon products. Stronger IP enforcement could help defend the company’s competitive position and future refrigerant revenue. Chemours and Local Officials Take Action to Protect Refrigerant Intellectual Property at Chillventa
• Neutral Sentiment: Several firms announced that investors who purchased CC securities between February 20 and August 4, 2026 may seek lead-plaintiff status in a federal class action. The deadline is December 7, 2026; these announcements primarily provide legal information and do not establish wrongdoing. Chemours Investor Alert
• Negative Sentiment: The lawsuits allege that Chemours and certain executives made material misstatements or omissions about the reliability of financial guidance and the strength of Opteon demand. One allegation is that aftermarket prebuying shifted refrigerant sales from 2026 into 2025, making the company’s prior outlook too optimistic. Pomerantz Class Action Against Chemours
• Negative Sentiment: Investors are also weighing the underlying earnings disappointment: Chemours’ latest reported quarterly revenue was below consensus, earnings per share missed estimates, and revenue declined year over year. The combination of weaker guidance, demand concerns, and potential litigation is keeping the stock under pressure despite intermittent rebounds.

Insiders Place Their Bets

In related news, insider Calderon Gerardo Familiar acquired 1,935 shares of the business's stock in a transaction that occurred on Wednesday, August 12th. The stock was purchased at an average cost of $15.53 per share, for a total transaction of $30,050.55. Following the transaction, the insider directly owned 58,547 shares of the company's stock, valued at approximately $909,234.91. This trade represents a 3.42% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Shane Hostetter bought 3,350 shares of Chemours stock in a transaction that occurred on Thursday, August 6th. The stock was bought at an average cost of $14.94 per share, for a total transaction of $50,049.00. Following the purchase, the chief financial officer owned 102,698 shares in the company, valued at $1,534,308.12. This represents a 3.37% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders acquired 8,663 shares of company stock worth $130,601. Insiders own 0.85% of the company's stock.

About Chemours

The Chemours Company NYSE: CC is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.

Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Chemours Company (NYSE:CC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.